Express News | Anhui Anke Biotechnology: The controlling Shareholder and actual controller have not reduced their shareholding in the company and have prematurely terminated the shareholding plan.

BreakingsFeb 24 18:35

Director Zhao Hui of Anhui Anke Biotechnology (300009.SZ) has completed a Shareholding reduction, totaling 0.2 million shares.

Anhui Anke Biotechnology (300009.SZ) announced that the shareholding reduction plan of Director Zhao Hui has been completed, as of 2025...

Zhitong FinanceFeb 17 20:09

Express News | Anhui Anke Biotechnology plans to participate in the subscription of Weisheng Pharmaceutical's Hong Kong initial public offering shares for no more than 31 million US dollars.

BreakingsFeb 11 21:17

Express News | Anhui Anke Biotechnology: The wholly-owned subsidiary's Cefaclor dispersible tablets have passed the consistency evaluation of generic drug quality and efficacy.

BreakingsFeb 11 18:37

Anhui Anke Biotechnology (300009): intends to make cornerstone investment in Weisheng Pharmaceutical to complement each other's resource integration advantages.

Event summary: On February 11, 2025, the company released an announcement regarding its participation as a cornerstone investor in the Hong Kong initial public offering of Weisheng Pharmaceutical. The company held the 17th meeting of the 8th Board of Directors on February 10, 2025.

SinolinkFeb 11 00:00

Anke Biotechnology Gets China Clinical Trial Nod for Growth Hormone Drug

MT NewswiresFeb 7 16:32